Schrödinger faces financial losses amid investment in experimental drugs. Key 2025 trial results will reveal its future ...

Casas, MD, discusses a systematic review of recent trials examining objective response rate and adverse events of antibody drug conjugate (ADC) combinations in advanced urothelial cancer.

Results from the company’s Talapro-2 trial saw a 38% reduction in the risk of death among HRR-mutated patients.

Review of data from the trial found that the vaccine was not sufficiently effective at preventing invasive E coli disease ...

After weeks of disruption to scientific federal grants, the National Institutes of Health has fallen behind in funding ...

Corbus Pharmaceuticals presented Phase 1 data on CRB-701 at ASCO GU, showing safety, tolerability, and responses across multiple tumor types.

Alphamab Oncology has dosed the first subject in the randomised Phase III JSKN003-306 trial of its anti-human epidermal ...

Two months after Allogene abandoned plans for its CAR-T in leukemia, analysts have suggested that fresh phase 1 data in ...

If AV-1 shows promising results in this clinical trial, researchers may pursue further clinical evaluations of its safety and ...

Swedish biotech company Gesynta Pharma AB has secured $27 million in a Series B financing round led by Innovestor Life Science in Finland.

IN8bio is accelerating patient enrollment in the INB-100 program and expects to complete enrollment of the expansion cohort in 2025. The company's FDA discussions confirmed that relapse-free survival ...

EXCLUSIVE: Retired David Mather was dealt a shocking blow when told his tiredness was stage-IV lung cancer - now a new UK ...